HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New York's Halt On Sales To Minors Could Catch More Than Weight Loss, Bodybuilding Products

Executive Summary

“What are retailers going to do? They're either going to put it behind a case or they're going to put it in a pharmacy-only counter where you have to ask for assistance to get it,” says CRN CEO Steve Mister. “Until we have some more insight, we're being over inclusive in terms of what we're including,” says attorney Claudia Lewis.

You may also be interested in...

NPA Complaint For Preemption Argues New York Swings Wildly With Age-Restricted Sales Law

New York law crosses so many federal regulations it would also affect Rx drug sales while allowing consumers to file complaints alleging businesses violate the law, NPA argues in complaint filed in federal court in New York City.

Will Constitution Stop New York's Diet Pill Sales Rule Despite State Age-Restricting DXM OTCs?

NPA argues in complaint that limiting purchases of weight loss and bodybuilding OTC drugs and supplements to consumers 18 and older preempted not only by FD&C Act regulations but also by Commerce Clause of the US Constitution.

Alli Return In U.S. Fattens Glaxo’s Consumer Outlook

GSK Consumer Healthcare says alli would be available starting Feb. 25 in most stores in the U.S. and Puerto Rico in “improved tamper-evident packaging.” Despite the product’s checkered history, its return marks another boost for Glaxo’s consumer outlook.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts